US 12,472,215 B2
Lactobacillus helveticus strain and composition containing same for prevention or treatment of inflammatory diseases
Bo Gie Yang, Seoul (KR); Myung Ho Jang, Seoul (KR); Chang Ho Kang, Chungju-si (KR); and Nam Soo Paek, Seoul (KR)
Assigned to GI BIOME, Seongnam-si (KR); and MEDIOGEN CO., LTD., Jecheon-si (KR)
Appl. No. 17/904,939
Filed by GI BIOME, Seongnam-si (KR); and MEDIOGEN CO., LTD., Jecheon-si (KR)
PCT Filed Feb. 25, 2021, PCT No. PCT/KR2021/002389
§ 371(c)(1), (2) Date Aug. 24, 2022,
PCT Pub. No. WO2021/172900, PCT Pub. Date Sep. 2, 2021.
Claims priority of application No. 10-2020-0023297 (KR), filed on Feb. 26, 2020.
Prior Publication US 2023/0158087 A1, May 25, 2023
Int. Cl. A61K 35/747 (2015.01); A23L 33/135 (2016.01); A61P 1/00 (2006.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A61P 1/00 (2018.01); C12N 1/20 (2013.01); C12R 2001/225 (2021.05)] 9 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising, as an active ingredient, lactic acid bacteria consisting of a Lactobacillus helveticus strain deposited as Accession No. KCTC 14110BP or a culture thereof, wherein the pharmaceutical composition is formulated into an oral formulation, wherein the formulation for oral administration is tablets, pills, capsules, gels, syrups or suspensions.